Strategic partnerships BrainXell collaborates with both large and small biotech and pharmaceutical partners to develop products, services, and applications using its proprietary iPSC-derived neuron technology, presenting opportunities for co-development, licensing, and joint ventures.

Therapeutic pipeline Lead program BXT-110 targeting Parkinson’s disease is IND-enabling, signaling near-term commercialization potential and the need for safety/toxicity, biomarker, and CMC support from potential contract research, manufacturing, and clinical service partners.

Integrated platforms Recent expansions into New Approach Methodology NAM platforms and integrated CNS complexity platforms create demand for validated disease models, toxicity testing suites, and reproducible human cell systems for drug discovery and preclinical testing.

Global reach & presence Operations anchored in Madison with Therapeutics activities in San Diego, plus collaborations with academic programs, provide access for regional pilots, pilot-scale manufacturing, and site-specific business development opportunities.

Data and tech enablement Tech stack and cloud-enabled workflows (MySQL, Google Cloud) alongside modular, scalable human cell systems offer sellable data platforms, assay services, and reproducible in vitro models to drug discovery teams.